Synthesis and Cytotoxicity of Novel 3-Amino-4-indolylmaleimide Derivatives

다국어 초록 (Multilingual Abstract)

In an attempt to develop potent and selective antitumor agents, a series of novel 3-amino-4-indolylmaleimides were designed and synthesized. The reaction showed high regioselectivity. The structure of compound 7a was determined by an X-ray single crystal diffraction method. The cytotoxicities of the title compounds were evaluated against HeLa, SMMC 7721 and HL 60 cancer cell lines by a standard MTT assay in vitro. The pharmacological results showed that some of the title compounds displayed moderate or high cytotoxic activity against the tested cell lines. Compound 7d was the most promising compound against the tested cancer cell lines. Structure-activity relationships are discussed based on the experimental data obtained. A hydroxyethylamino group at the 3-position in the side chain of indolylmaleimide is associated with an increase in cytotoxicity.

참고문헌 (Reference)

1 Tanaka, M., "Synthesis, SAR studies, and pharmacological evaluation of 3-anilino- 4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCβ-selective inhibitors" 14 : 5781-5794, 2006

2 Brenner, M., "Synthesis of arcyriarubin b and related bisindolylmaleimides" 44 : 2887-2892, 1988

3 Tanaka, M., "Synthesis of anilino-monoindolylmaleimides as potent and selective PKCβ inhibitors" 14 : 5171-5174, 2004

4 Zhao, S. Y., "Synthesis and cytotoxicity of novel 3-amido-4-indolylmaleimide derivatives" 3 : 198-200, 2009

5 Tamaoki, T., "Staurosporine, a potent inhibitor of phospholipid/Ca2+ dependent protein kinase" 135 : 397-402, 1986

6 Jiang, D.-F., "Regioselective amination of 3-bromoindolylmaleimide with amines" 7 : 144-148, 2010

7 Zhao, S.-Y., "Recent progress in indolylmaleimide derivatives as protein kinase C inhibitors" 28 : 1676-1684, 2008

8 Scharf, H. D., "Preparative photochemical C4-ring synthesis. I" 98 : 764-780, 1965

9 Schultz, M., "Preparation of 4-(3-indolyl)maleimides as antiallergics and immunotherapeutic agents"

10 Serova, M., "Preclinical and clinical development of novel agents that target the protein kinase C family" 33 : 466-478, 2006

11 Rucci, N., "Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases" 8 : 342-349, 2008

12 Dodo, K., "Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives" 15 : 3114-3118, 2005

13 Ali, A. S., "Exploitation of protein kinase C: a useful target for cancer therapy" 35 : 1-8, 2009

14 Chen, Y. B., "Enzastaurin" 17 : 939-944, 2008

15 Wagner, J., "Discovery of 3-(1H-indol- 3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole -2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes" 52 : 6193-6196, 2009

16 He, M., "Design and synthesis of new leads for PKC bisubstrate inhibitors" 4 : 2845-2850, 1994

17 Fujita, Y., "Clinical approaches toward tumor angiogenesis: past, present and future" 14 : 3820-3834, 2008

18 Martiny-Baron, G., "Classical PKC isoforms in cancer" 55 : 477-486, 2007

19 Pajak, B., "Bisindolylmaleimides in anti-cancer therapy-more than PKC inhibitors" 53 : 21-31, 2008

20 Levy, D. E., "Aryl-indolylmaleimides as inhibitors of CaMKII δ. Part 1: SAR of the aryl region" 18 : 2390-2394, 2008

21 Argyriou, A. A., "Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas" 77 : 1-11, 2009

22 Jirousek, M. R., "(S)- 13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9: 16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ" 39 : 2664-2671, 1996